Top Authors

• Most frequent coverage on MITI

• 
  Ohad Hammer (176 followers)

  • Immunogen's Busy Month, Part II (Wed, Dec 2)
  • Micromet: The Clock Is Ticking (Mon, Aug 24)
  • Top Biotech Picks for ASCO 2009 (Part II) (Wed, May 27)

  More by Ohad Hammer on MITI »
• 
  Alan Brochstein (710 followers)

  • Cancer Stocks: Lagging Again (Mon, Jul 16)
  • Cancer Stocks: Tracking the Market (Mon, Jul 9)
  • Cancer Stocks: The Bleeding Slows (Mon, Jul 2)

  More by Alan Brochstein on MITI »
• 
  Centient Biotech Investor (10 followers)

  • Week In Review: Biotech Slides Slightly Lower (Mon, Mar 19)
  • Biotech In Review: Adams Respiratory Guides Lower (Sun, Mar 18)
  • Biotech Week-in-Review: Genentech, Amgen Take a Toll on Biotech (Mon, Jan 29)

  More by Centient Biotech Investor on MITI »

• Most followed authors on MITI

• 
  Bespoke Investment Group (3511 followers)

  • Best Performing Stocks Since 3/9/09 and 10/9/07 (Thu, Nov 12)

  More by Bespoke Investment Group on MITI »
• 
  Mike Havrilla (1924 followers)

  • FDA Calendar Updates: Keryx Biopharma Announces Phase 2 Results (Tue, Jun 9)

  More by Mike Havrilla on MITI »
• 
  Zacks.com (1054 followers)

  • Micromet: Drug Development Update (Tue, Apr 28)

  More by Zacks.com on MITI »

• Newest authors on MITI

• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on MITI »
• 
  Prohost Biotech (88 followers)

  • Micromet: Opportunity Lies in Breakthrough BiTE Antibody (Wed, Dec 16)

  More by Prohost Biotech on MITI »
• 
  M. E. Garza (518 followers)

  • Big Lineup of Healthcare Stocks Crack the Russell 3000 Index (Wed, Jul 1)

  More by M. E. Garza on MITI »

• Most commented on MITI

• 
  Ohad Hammer (176 followers)

  • Immunogen's Busy Month, Part II (Wed, Dec 2)
  • Micromet: The Clock Is Ticking (Mon, Aug 24)
  • Top Biotech Picks for ASCO 2009 (Part II) (Wed, May 27)

  More by Ohad Hammer on MITI »
• 
  Justin M. Hall (672 followers)

  • Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers (Sun, Sep 20)
  • Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up (Fri, Sep 11)

  More by Justin M. Hall on MITI »
• 
  Alan Brochstein (710 followers)

  • Cancer Stocks: Lagging Again (Mon, Jul 16)
  • Cancer Stocks: Tracking the Market (Mon, Jul 9)
  • Cancer Stocks: The Bleeding Slows (Mon, Jul 2)

  More by Alan Brochstein on MITI »